A citation-based method for searching scientific literature

Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen. BMJ Open 2015
Times Cited: 9







List of co-cited articles
34 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
44

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
Lindsay B Harrison, Pablo F Mora, Gregory O Clark, Ildiko Lingvay. J Investig Med 2013
35
44

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
Gayatri Sarkar, May Alattar, Rebecca J Brown, Michael J Quon, David M Harlan, Kristina I Rother. Diabetes Care 2014
51
33

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
55
33

Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
33

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
33



Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen, Michael E J Lean. Lancet 2009
613
33

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
72
33

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Amy G Egan, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh. N Engl J Med 2014
316
22

Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
Andrea N Traina, Melinda E Lull, Adrian C Hui, Toni M Zahorian, Jane Lyons-Patterson. Can J Diabetes 2014
33
22

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2015
22


Incretin hormones and the satiation signal.
J J Holst. Int J Obes (Lond) 2013
94
22

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
389
22

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Keith C Ferdinand, William B White, David A Calhoun, Eva M Lonn, Philip T Sager, Rocco Brunelle, Honghua H Jiang, Rebecca J Threlkeld, Kenneth E Robertson, Mary Jane Geiger. Hypertension 2014
82
22


Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
J Dupre, M T Behme, I M Hramiak, P McFarlane, M P Williamson, P Zabel, T J McDonald. Diabetes 1995
121
22

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
22



Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
50
22

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Richard E Pratley, Michael A Nauck, Anthony H Barnett, Mark N Feinglos, Fernando Ovalle, Illana Harman-Boehm, June Ye, Rhona Scott, Susan Johnson, Murray Stewart,[...]. Lancet Diabetes Endocrinol 2014
213
22


Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
335
22


Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Kathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, José G González González, Charles Atisso, Whitney Sealls, Jessie L Fahrbach. Lancet 2014
270
22


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
22

Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.
S S Lund, L Tarnow, A S Astrup, P Hovind, P K Jacobsen, A C Alibegovic, I Parving, L Pietraszek, M Frandsen, P Rossing,[...]. Diabetes Obes Metab 2009
29
22

The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Iben Brock Jacobsen, Jan Erik Henriksen, Henning Beck-Nielsen. Basic Clin Pharmacol Toxicol 2009
35
22


An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Evis Harja, Jonathan Lord, Jay S Skyler. Diabetes Technol Ther 2013
22
11

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
731
11

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
S Bonner-Weir, P A In't Veld, G C Weir. Diabetes Obes Metab 2014
43
11

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
11

Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Jean-Luc Faillie, Samy Babai, Sabrina Crépin, Virginie Bres, Marie-Laure Laroche, Hervé Le Louet, Pierre Petit, Jean-Louis Montastruc, Dominique Hillaire-Buys. Acta Diabetol 2014
51
11

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
255
11

Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
Urd Kielgast, Jens J Holst, Sten Madsbad. Curr Diabetes Rev 2009
37
11

Incretins and risk of neoplasia.
Thorvardur R Halfdanarson, Rahul Pannala. BMJ 2013
8
12

Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients.
D Bruttomesso, C Fongher, B Silvestri, S Barberio, M C Marescotti, E Iori, A Valerio, D Crazzolara, A Pianta, A Tiengo,[...]. Diabetes Res Clin Pract 2001
9
11

Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.
Teresa Vanessa Fiorentino, Michael Owston, Gregory Abrahamian, Stefano La Rosa, Alessandro Marando, Carla Perego, Eliana S Di Cairano, Giovanna Finzi, Carlo Capella, Fausto Sessa,[...]. Am J Pathol 2015
12
11



Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.
Nathan R Hill, Nick S Oliver, Pratik Choudhary, Jonathan C Levy, Peter Hindmarsh, David R Matthews. Diabetes Technol Ther 2011
169
11


Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
Prabhakar Viswanathan, Ajay Chaudhuri, Ruchi Bhatia, Fida Al-Atrash, Priya Mohanty, Paresh Dandona. Endocr Pract 2007
106
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.